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Clinical guidance is often sought when prescribing drugs for patients with
primary mitochondrial disease. Theoretical considerations concerning drug
safety in patients with mitochondrial disease may lead to unnecessary withhold-
ing of a drug in a situation of clinical need. The aim of this study was to develop
consensus on safe medication use in patients with a primary mitochondrial
disease. A panel of 16 experts in mitochondrial medicine, pharmacology, and
basic science from six different countries was established. A modified Delphi
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technique was used to allow the panellists to consider draft recommendations
anonymously in two Delphi rounds with predetermined levels of agreement.
This process was supported by a review of the available literature and a con-
sensus conference that included the panellists and representatives of patient
advocacy groups. A high level of consensus was reached regarding the safety
of all 46 reviewed drugs, with the knowledge that the risk of adverse events is
influenced both by individual patient risk factors and choice of drug or drug
class. This paper details the consensus guidelines of an expert panel and pro-
vides an important update of previously established guidelines in safe medi-
cation use in patients with primary mitochondrial disease. Specific drugs,
drug groups, and clinical or genetic conditions are described separately as
they require special attention. It is important to emphasise that consensus-
based information is useful to provide guidance, but that decisions related to
drug prescribing should always be tailored to the specific needs and risks of
each individual patient. We aim to present what is current knowledge and
plan to update this regularly both to include new drugs and to review those
currently included.
KEYWORD S
drugs, in vitro studies, in vivo studies, mitochondrial diseases, mitochondrial toxicity, safety
1 | INTRODUCTION
Mitochondrial diseases are a group of inherited metabolic
disorders that can present at any age and often exhibit
multisystem involvement and high morbidity and mortal-
ity.1 The prevalence is conservatively estimated at 1 in
4300 live births.2 The natural course of these diseases is
progressive and currently no disease-modifying therapies
are available for the vast majority. Important consider-
ations in the management of patients with mitochondrial
diseases include early treatment of organ-specific compli-
cations and avoidance of potential triggers of decompensa-
tion including catabolic stressors (eg, fasting, intercurrent
illness, pyrexia, trauma, or surgery) or medications that
are toxic to mitochondrial function.3
For pharmacological treatment of patients risk-benefit
considerations and a search for safer, better tolerated or
more effective alternatives are part of normal clinical prac-
tice. Prescribing drugs to patients with mitochondrial dis-
ease is associated with the additional consideration of the
drug's potential to negatively influence mitochondrial
function.4 Due to the heterogeneity in manifestations of
mitochondrial disease, reported effects of a pharmacologic
agent in an individual patient do not automatically
account for all mitochondrial patients.
Mechanisms of drug-induced mitochondrial toxicity
observed in pre-clinical models include: (a) inhibition of
one or more of the electron transport chain complexes
(ETCs); (b) uncoupling of mitochondrial oxidative phos-
phorylation (OXPHOS) by dissipation of the membrane
potential and thus disconnecting the ETC from ATP
synthase; (c) inhibition of mitochondrial OXPHOS by
binding to ATP synthase; (d) inhibition of mitochondrial
protein synthesis and biogenesis by affecting mitochon-
drial DNA (mtDNA) replication and/or fusion of mito-
chondria; and (e) formation of reactive oxygen species
(ROS) as a consequence of any or all of the four above-
mentioned mechanisms.5
Clinical guidelines on the safe use of medications in
patients with mitochondrial disease are available but sub-
stantial practice variation is a potential source of outcome
disparity. Reasons for this have included the paucity of
high-quality evidence and the historical lack of screening
for mitochondrial toxicity in drug development. For the
vast majority of existing licensed drugs, mitochondrial
toxicity is unknown. Thus, when evaluating drug safety
in patients with a mitochondrial disease, we must rely on
information from in vitro and in vivo pre-clinical studies
and published case reports. Many studies have investi-
gated drug side effects by analysing mitochondrial
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function in healthy cell lines exposed to high doses of
these compounds. It is very difficult to extrapolate these
results to what would happen in cells from patients, or
what the clinical consequences might be in vivo for
patients with mitochondrial disease.
Conscious of the lack of available evidence, we con-
vened a workshop aimed at developing a consensus
about safe medication use in patients with a primary
mitochondrial disease. Consensus was based on a
review of the literature and the clinical experience of
paediatricians, internists and neurologists experienced
in treating affected patients. The results of this Delphi
workshop were used to develop guidance for physi-
cians prescribing drugs for patients with mitochondrial
diseases. This article does not contain any studies with
human or animal subjects performed by any of the
authors.
2 | METHODS
A modified Delphi-based technique was used to develop
a consensus view of drug safety in patients with a mito-
chondrial disease by a group of internationally acknowl-
edged experts. The Delphi technique was developed by
the RAND (research and development) Corporation in
1953 to elicit and process value judgments.6 The tech-
nique consists of a structured and repetitive survey of at
least two rounds, which continues until consensus is
reached among panellists. Between each round, feedback
is provided to the panellists.
2.1 | Formation of panellists
Clinicians and researchers with expertise in mitochon-
drial medicine and pharmacology were invited. Poten-
tial participants were selected based on their known
experience in the field of mitochondrial medicine and
pharmacology. To broaden the panel of experts, we
also asked invitees to provide names of other potential
participants. Since drug prescription could vary from
country to country and from continent to continent, we
endeavoured to achieve geographical balance in the
selection of panellists. Candidate panellists were
invited by e-mail outlining the study aims and the Del-
phi process. Patient representatives from the Interna-
tional Mito Patients advocacy group IMP (https://
www.mitopatients.org/) were also invited. The consen-
sus panel finally consisted of 16 participants and two
patient representatives from IMP. All the participants
are experts in mitochondrial medicine, including 13 cli-
nicians, two pharmacologists and a basic scientist.
Participants were from five different European coun-
tries and from the USA.
2.2 | Selection of drugs
Due to the limited duration of the workshop (2 days), only a
finite number of drugs could be considered and drugs to be
studied were, therefore, selected by using a previously publi-
shed list on the website of the patient advocacy group IMP
(https://www.mitopatients.org/mitodisease/potentially-
harmful-drugs) supplemented with a few drugs com-
monly prescribed to patients affected by mitochondrial
disease (eg, anaesthetic agents, analgesics, antibiotics,
antiepileptic drugs). Two facilitators (MM and MdV)
formulated a list of 32 drugs and drug classes and circu-
lated this to the panellists. Subsequently, panellists had
the opportunity to add drugs which were in their view
most needed a consensus opinion. Due the limited time,
the total number of drugs/drug classes was limited to
46. The decision to study some drugs as a group was
based on the fact that the class of drugs have a common
pharmacological mode of action or similar off-target
side effects.
2.3 | Delphi-based process
The process was performed in three stages (Figure 1).
1. Preparatory phase: Potential panellists were invited
and the list of drugs and drug classes to be studied
was compiled. Each panellist was assigned 2 to 4 drugs
or drug classes and was asked to perform a thorough
literature search from recognised medical databases.
Participants were requested to send a one page sum-
mary of their results, including the following items:
mode of action; theoretical effect on mitochondrial
function; known effects on mitochondrial function;
effects observed in patients with mitochondrial dis-
ease, cell lines from patients with mitochondrial dis-
ease or control cell lines; what type of study (eg, case
report, in vitro) and a comprehensive list of references
consulted during the review process. The panellists
were also asked to submit one or two statements
about the drugs they had investigated, including a
statement about the safety of the drug in patients with
mitochondrial disease.
2. First Delphi round: The literature reviews of the drugs
were summarised. All panellists were provided with
this bundle of drug summaries, as background infor-
mation, before they were requested to give their opin-
ion in the first voting round. The statements were
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rewritten by the facilitators and sent to all panellists
by an online survey (ie, Google Form), who had the
opportunity to indicate their agreement anonymously
on a linear five-point scale anchored at each end by
‘Score 1: Absolutely disagree’ and ‘Score 5: Absolutely
agree’. Opportunity was provided for participants to
add comments in order to correct areas of ambiguity
or suggestions for improvement. Strong consensus
agreement was predefined as the mean result ≥4
and ≥70% agreement among the panellists (scores of
4 or 5 on the linear scale). If only one of these two
criteria was met, good consensus was considered. If
neither consensus criteria was met, then the statement
was considered to lack consensus agreement. State-
ments that did not achieve consensus in the initial
round were scheduled for discussion at the workshop
as pre-agreed.
3. Second Delphi round: This phase took place during a
two-day workshop. During the workshop, panellists
were provided with feedback regarding the drugs for
which the statements had not reached consensus. The
feedback consisted of presentations of the literature
search. After each presentation, there was an opportu-
nity to ask questions, to comment and to exchange
personal experiences in prescribing the specific drug
in question. At the end of each session during which
seven to nine drugs had been discussed, the panellists
were asked to re-rate the statements concerning these
drugs by the online survey, that is, the second voting




































case presentation (n= 40)
final consensus (n= 46)
invite panelists + selection
of initial drug(class) (n= 32)
add relevant drugs or
drug classes
comprehensive literature 
review and compose 
queries (n= 46)
select final drug and drug
class list (n= 46)
consensus
(n= 40)
FIGURE 1 Flowchart of the
Delphi-based process showing the
activities and results of the three
stages. n = number of drugs/drug
groups
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4 or 5 Consensus
General
We need to update the IMP table of potentially harmful drugs for
mitochondrial patients version 3 (https://www.mitopatients.org/
mitodisease/potentially-harmful-drugs)
4.87 100 Strong
Good clinical practice including general indications, contraindications,
clinical monitoring and side effects for all drugs must always kept in
mind (with or without mitochondrial genetic defect). They will not
be discussed in this consensus
4.94 100 Strong
For all drugs where clear evidence in vivo of mitochondrial toxicity is
absent or poor, they can be used with careful monitoring in the first
few days of treatment for potential side effects and measurement of
blood lactate
4.19 93.7 Strong
There is a great need for further studies to determine a) the criteria for
drug mitochondrial toxicity in humans, and b) which specific drugs
are toxic for mitochondria and must be avoided
4.25 75 Strong
Analgesics-Antipyretics-NSAIDs-Corticosteroids
Paracetamol is not contraindicated in primary mitochondrial disease
(PMD)
4.56 87.5 Strong
Do you consider that steroids are safe to use in acutely ill patients with
PMD?
4.46 100 Strong
It is safe to use steroids in patients with Kearns-Sayre syndrome 4.13 86.6 Strong
NSAIDs can be safely used in PMD 4.31 87.5 Strong
It is reasonable to avoid NSAIDs for long periods in PMD with renal or
hepatic or gastrointestinal involvement
4.31 93.75 Strong
Use of aspirin is safe in PMD 4.56 93.75 Strong
Alcohol
Alcohol in large amounts (above recommended daily intake) is
generally toxic and should be avoided
4.37 93.75 Strong
Alcohol consumption within the limits recommended by national
guidelines appears non-toxic in PMD
5 100 Strong
Anaesthetics
It is safe to use articaine in PMD 4.75 100 Strong
It is safe to use bupivacaine in PMD 4.81 100 Strong
It is safe to use lidocaine in PMD 5 100 Strong
It is safe to use volatile anaesthetics in PMD 4.62 100 Strong
It is safe to use fentanyl in PMD 4.75 100 Strong
Ketamine is safe in general anaesthesia for patients with PMD 4.75 100 Strong
Barbiturates are safe in general anaesthesia for patients with PMD 4.56 93.75 Strong
Propofol is safe in induction anaesthesia in PMD 3.81 81.25 Consensus
Extra caution and monitoring should be considered for patients with
PMD manifesting predominantly with myopathic phenotype when
neuromuscular blockade is required for general anaesthesia and
surgery
4.25 87.5 Strong
Non depolarizing neuromuscular blocking agents are safe for general
anaesthesia in patients with PMD
4.56 100 Strong
(Continues)





4 or 5 Consensus
Antibiotics
As a general approach, short term (< 7 days) antibiotic treatment is
unlikely to be a problem in PMD. Infection is a much greater risk
than short term antibiotics
4.75 100 Strong
If indicated, linezolid could be used in mitochondrial disease, with
careful lactate monitoring, particularly in children and other patients
with pre-existent lactic acidaemia
4.56 100 Strong
It is safe to use quinolones in PMD 4.44 100 Strong
Aminoglycosides should be avoided in patients with predisposing
mitochondrial DNA mutations (eg, m.1555A > G and m.1494C > T)
for ototoxicity
4.81 100 Strong
Topical chloramphenicol use is safe in PMD 4.62 100 Strong
It is safe to use tetracyclines in PMD 4.75 100 Strong
It is safe to use ceftriaxone in PMD 4.87 100 Strong
Antidepressant-Neuroleptic drugs
The use of antipsychotics medications when they are clinically
indicated is not contraindicated in PMD
4.19 87.5 Strong
Quetiapine can be safely used in PMD despite some studies in rodents
or cell lines indicate potential mitochondrial toxicity
4.31 93.75 Strong
Fluphenazine could be safely used in PMD 4 75 Strong
Haloperidol can be safely used in PMD despite some studies in rodents
or cell lines indicate potential mitochondrial toxicity
3.81 75 Consensus
It is safe to use tricyclic antidepressants in PMD 4.87 100 Strong
It is safe to use chlorpromazine in PMD 4.75 100 Strong
It is safe to use clozapine in PMD 4.56 100 Strong
It is safe to use risperidone in PMD 4.56 100 Strong
Antidiabetic drugs
It is safe to use metformin in PMD 4.56 100 Strong
It is safe to use glitazone in PMD 4.37 100 Strong
Antiepileptic drugs
Since there are no descriptions of toxicity of midazolam or other
benzodiazepines (BDZ) in PMD, it is correct to assume that
midazolam or other BDZ could be used in acute seizure in PMD, or
be used as anaesthetic
4.56 100 Strong
Valproic acid should be avoided only in POLG patients 4.25 81.25 Strong
In non-POLG patients with mitochondrial disease, without liver
disease, valproic acid could be used to manage refractory epilepsy
and refractory mood disorders
4.4 100 Strong
Carbamazepine is safe in PMD 4.12 75 Strong
Oxcarbazepine is not contraindicated in PMD 4.37 93.75 Strong
Oral phenobarbital is safe in patients with PMD 4.6 100 Strong
In refractory mitochondrial status epilepticus, barbiturates in
appropriate settings could be used for long duration infusion
4.53 100 Strong
It is safe to use gabapentin in PMD 4.86 100 Strong
(Continues)
DE VRIES ET AL. 805
agreement for each statement. Consensus was pre-
defined as in the first Delphi round.
3 | RESULTS
3.1 | Preparatory phase
In the preparatory phase the participants performed and
summarised a literature review regarding the drugs or
drug groups they were asked to study (see Supplementary
data for the summaries of these literature reviews). Fur-
thermore, a total of 55 statements for the voting rounds
were composed by the participants to cover the selected
46 drugs/drug groups.
3.2 | Delphi rounds
All the participants responded in the first Delphi round,
all of them participated in the workshop meeting and all
of them responded in the second voting round. During
the first voting round, prior to the workshop meeting,
consensus was not achieved for 40 drugs owing to a low
level of agreement (<70% and/or <4). Good or strong
consensus was reached for six drugs or drug groups;
enalapril, paracetamol, midazolam, carbamazepine,
oxcarbazepine, and haloperidol.
According to our pre-agreed Delphi process, the levels
of evidence in the available literature pertaining to drugs
that did not reach consensus were discussed during the
meeting. The main point of discussion for each drug was
the knowledge gap between pre-clinical drug studies and
how these relate to the patient with a mitochondrial dis-
ease. Drug effects measured in vitro or in vivo were either
not, or not fully, translatable to clinical consequences for
the patient for several reasons. Most studies were
designed to investigate toxicity of the drug, and conse-
quently examined the effects of extremely high drug
doses (ie, to certify the occurrence of a toxic response and
associated off-target mechanisms). Therapeutic drug
levels would plausibly show less or no negative effects on
mitochondrial function. Moreover, cell lines used in the
majority of studies did not have a primary mitochondrial
defect and thus none of the compensatory processes asso-
ciated with mitochondrial dysfunction. Investigating the
effects of drugs in cell lines from patients with primary
mitochondrial disease was therefore considered worth-
while. In several studies, the formation of ROS was used
as an outcome parameter; however, in many cases,





4 or 5 Consensus
It is safe to use phenytoin in PMD 4.33 86.66 Strong
It is safe to use levetiracetam in PMD 4.86 100 Strong
It is safe to use perampanel in PMD 4.13 80 Strong
It is safe to use topiramate in PMD 4.46 100 Strong
In refractory mitochondrial status epilepticus, propofol is safe for long
duration infusion (up to 48 hours)
4.47 100 Strong




It is safe to use bisphosphonates in PMD 4.25 100 Strong
Cardiovascular drugs
It is safe to use amiodarone in PMD 4.06 93.3 Strong
It is safe to use beta-blockers in PMD 4.46 100 Strong
Enalapril is safe in PMD 4.06 81.25 Strong
Fibrate drugs-Statins
It is safe to use fibrate in PMD 4.62 100 Strong
It is safe to use statins in PMD as long as guidelines concerning
monitoring of CK and symptoms are followed
4.5 100 Strong
Abbreviation: PMD, primary mitochondrial disease.
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mitochondrial or extra-mitochondrial, was not demon-
strated. After discussing and weighing the pre-clinical
data, the expert team discussed their own clinical
experiences of observed safety or side effects of the
drug(s) in question in patients with mitochondrial
disease.
FIGURE 2 Voting results of the final Delphi round, showing the distribution of votes per statement
TABLE 2 Points of attention regarding drug prescription in patients with a mitochondrial disease (detailed description in Section 4)
Specific drug/drug group/clinical
condition/genotype Points of attention
Specific drug/drug group/genotype
Aminoglycosides The mitochondrial 12S rRNA is a hot spot for mutations associated with both aminoglycoside-
induced and non-syndromic hearing loss. Screening for these mtDNA mutations is strongly
recommended before elective long-term treatment is planned. The benefits of the drug in
emergency treatment, as a very effective broad-spectrum antibiotic, outweigh the risks in
these situations.
Valproic acid Should be used only in exceptional circumstances. The drug is absolutely contraindicated in
patients with mitochondrial disease due to POLG mutations. Valproic acid should not be
used in patients with known liver disease and/or clinical signs suspicious for POLG disease.
Neuromuscular blocking agents Extra caution and monitoring should be performed for patients manifesting a predominantly
myopathic phenotype.
Specific clinical condition
General anaesthesia and surgery Catabolism should be prevented by minimising preoperative fasting and administering
intravenous glucose perioperatively during prolonged anaesthesia, unless the patient is on a
ketogenic diet.
Duration of treatment The duration of drug administration may play a role in whether or not side effects develop.
Duration of treatment should be guided by individual patient needs and their response to
specific treatments.
Renal impairment Many patients with a mitochondrial disease have renal impairment; drug dose adjustment
should be considered particularly when active drug moieties are renally cleared.
Metabolic acidosis (lactic acidosis) Metabolic acidosis (lactic acidosis) may occur in patients with mitochondrial disease, therefore
drugs that can cause acidosis should be prescribed with caution. Regular clinical review and
monitoring of acid-base status in blood is recommended.
Abbreviation: PMD, primary mitochondrial disease.
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This process was followed by the second voting round.
Good or strong consensus was achieved for all the drugs or
drug groups. The consensus results for all the statements
are shown in Table 1 and Figure 2. Immediately following
the workshop, it was discussed that one of the statements
could have been (for the panellists) or could be (future use
of the information by colleagues) phrased misleadingly. It
concerned the statement about the use of steroids in
patients with primary mitochondrial disease. Therefore, a
more clearly defined statement was formulated and the
panellists were asked to vote on this statement via an online
survey. The result of this voting showed strong consensus.
The general conclusion of the Delphi process, all
based on consensus (level 4 evidence), was that all the
46 drugs or drug groups studied are considered to be gen-
erally safe for patients with mitochondrial disease
although some specific restrictions were considered for
certain molecular defects and particular clinical situa-
tions. These specific conditions will be reviewed in the
Discussion.
4 | DISCUSSION
In this study, 16 experts in mitochondrial medicine, phar-
macology and basic science provided their professional
opinion concerning the safe use of medications in
patients with primary mitochondrial disease, to assist cli-
nician and patient decision-making. During the Delphi-
based process, it became apparent that for many drugs
clinical experience conferred most weight, since these
observations reflected the effect of the drug in actual
patients with mitochondrial diseases. It is important to
emphasise that consensus-based information is useful to
provide guidance, but that decisions related to drug pre-
scribing should always be tailored to the specific needs
and risks of each individual patient. Recognising the
need for a personalised drug prescription is essential to
avoid the pitfalls of one-size-fits-all clinical standards,
especially in patients with a mitochondrial disease, a
group characterised by enormous clinical heterogeneity.
Moreover, good clinical practice, including general indi-
cations, contraindications, clinical monitoring and side
effects for all drugs must always be considered, whether
it is a patient with mitochondrial disease or not.
Some of the statements devised were genotype-spe-
cific. However, the majority could be applied generically
to the disease group (ie, mitochondrial disease) as a
whole. Caveats for certain drugs or class of drugs were
noted, as follows (Table 2).
1. Screening for mtDNA mutations associated with pre-
disposition to aminoglycoside susceptibility should be
considered before treatment with aminoglycosides.7
It is strongly recommended to screen for these
mtDNA mutations before elective long-term treatment
with aminoglycosides is planned. In some emergency
situations aminoglycosides provide very effective broad-
spectrum antibiotic treatment and should be prescribed
until immediate danger has passed or microbial sensitiv-
ities have been established and a suitable alternative
antibiotic can be administered. The benefits of the drug
outweigh the risks in these situations. The mitochon-
drial 12S rRNA is a hot spot for mutations associated
with both aminoglycoside-induced and non-syndromic
hearing loss. Of those, the homoplasmic m.1555A > G
and m.1494C > T mutations in the highly conserved
coding region of the 12S rRNA have been associated
with hearing loss worldwide.8
2. Valproic acid should be used only in exceptional cir-
cumstances. In most national guidelines for the
treatment of status epilepticus, valproic acid is not
the first choice drug. Furthermore, the drug is abso-
lutely contraindicated in patients with mitochon-
drial disease due to POLG mutations. Additionally,
valproic acid should not be used in patients with
known liver disease and/or clinical signs suspicious
for POLG disease, such as epilepsia partialis con-
tinua, explosive onset of focal epilepsy or rhythmic
high amplitude delta with superimposed spikes
(RHADS) on EEG.9
3. The last drug group that deserves particular atten-
tion is the group of neuromuscular blocking agents.
Extra caution and monitoring should be performed
for patients manifesting a predominantly myopathic
phenotype.
4. Although historically there have been largely theoreti-
cal concerns around general anaesthetic use in
patients with mitochondrial disease, adverse events
are exceptionally rare. Consensus was unanimous that
these drugs and drug classes were deemed safe. Gen-
eral surgery is a potentially risky procedure for any
patient with mitochondrial disease. Catabolism should
be prevented by minimising preoperative fasting and
administering intravenous glucose perioperatively
during prolonged anaesthesia, unless the patient is on
a ketogenic diet.3
5. The duration of drug administration may also play a
role in whether not side effects develop. Short term use
of midazolam is considered safe, for example, in the
acute management of epileptic seizures or for a short
anaesthetic procedure. In specific clinical situations, a
longer duration of administration of a certain drug can
be justified, despite an increased risk of side effects or
disease progression. This accounts for situations in
which no alternative treatment options are available
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and the absence of treatment could have a more detri-
mental effect of disease progression. Examples include
the use of propofol or barbiturate infusions in the man-
agement of refractory status epilepticus. Duration of
treatment should be guided by individual patient needs
and their response to specific treatments.
6. Many patients with a mitochondrial disease have renal
impairment, including patients with the m.3243A > G
mtDNA mutation or genetic defects in RMND1.10-12
Drug dose adjustment should be considered particu-
larly when active drug moieties are renally cleared, for
example, levetiracetam.
7. Metabolic acidosis (lactic acidosis) may occur in
patients with mitochondrial disease; therefore, drugs
that can cause acidosis should be prescribed with cau-
tion, with advice to report symptoms of metabolic aci-
dosis and regular clinical review and monitoring of
acid-base status in blood.
The present study has limitations. Although consen-
sus methods are widely used to inform clinical practice in
the absence of empirical data, expert judgement ranks
low in the hierarchy of evidence. However, we felt com-
pelled to give transparent opinions based on the available
preclinical studies and clinical evidence, to prevent unnec-
essary withholding of important drugs from patients with
primary mitochondrial disease.
A recurrent issue throughout our discussions was the
lack of translation between pre-clinical studies and the
clinical situation, where physicians experience that
patients appear to tolerate most drugs. Multiple factors
will be responsible for this lack of translation, for exam-
ple, exposure time. We analysed the compounds compar-
ing the Cmax values (ie, in vivo) or concentration ranges
(ie, in vitro) of the pre-clinical exposures employed along-
side the Cmax of the clinical dose used and human toxic
concentrations. The head-to-head comparisons can be
seen in Table 3. For only 18 out of 44 drugs or drug clas-
ses was the drug concentration employed in rodent or
cell models comparable with the therapeutic levels found
in clinical populations. This finding demonstrates that
the lack of translation to the clinical situation is due to
the use of higher or toxic drug levels in the majority of
pre-clinical studies.
Limitations were noticed as well in drawing recommen-
dations from published clinical series and case reports, due
to several factors. Many studies describe patients with a bio-
chemical defect in OXPHOS without mentioning a specific
mitochondrial genetic defect, that is, without confirmation
of primary mitochondrial disease. Furthermore, patients
often have co-morbidities and/or are using polypharmacy
making it impossible to determine whether the effects
reported are directly related to the drug in question or are
consequences of one of the other diseases or other drugs.
We plan to revise the existing list regularly and to
extend the list of drugs in the future using the same Delphi
process. The list of drugs studied will be freely available on
the web pages of centres of mitochondrial disease expertise
and the IMP. This provides the opportunity to easily revise
and update knowledge about the included drugs. Further-
more, given the frequent disparities between pre-clinical
studies and clinically relevant treatment doses, future pre-
clinical toxicity studies that more closely model patient
doses and conditions (ie, mitochondrial deficiencies) are
needed for improved drug-induced mitochondrial dysfunc-
tion assessments in mitochondrial patients.
5 | CONCLUSION
This study details the consensus guidelines of a mito-
chondrial expert panel on the safe use of medications in
patients with mitochondrial disease. We acknowledge
that the quality of available evidence or published litera-
ture used to accredit these recommendations is currently
limited. The key recommendations are: (a) valproate
should be avoided in patients with POLG-related mito-
chondrial disease and alternative anticonvulsants consid-
ered as first-line therapeutic strategies; (b) prolonged use
of specific drugs may have negative consequences and
should be avoided if good alternative treatment options
are available; and (c) the usual standards of good practice
prevail when prescribing any drug, irrespective of the
drug's mitochondrial toxicity potential or profile. We do
emphasise that drug prescriptions should always be tai-
lored to the individual patient after careful consideration
of their specific needs.
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